par Piccart-Gebhart, Martine 
;Muquardt, Carl ;Bosman, C;Pirotte, Pascal ;Veenstra, S;Grillo, Francesca;Leclercq, Guy
Référence Journal of the National Cancer Institute, 83, 21, page (1553-1559)
Publication Publié, 1991-11
;Muquardt, Carl ;Bosman, C;Pirotte, Pascal ;Veenstra, S;Grillo, Francesca;Leclercq, Guy Référence Journal of the National Cancer Institute, 83, 21, page (1553-1559)
Publication Publié, 1991-11
Article révisé par les pairs
| Résumé : | We examined the estrogen receptor measurement in 265 human breast cancer cytosols by using a specific method based on [3H]tamoxifen aziridine labeling, sequential immunoadsorption with an antiestrogen receptor monoclonal antibody (H-222), sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and autoradiography. These new tools of molecular endocrinology revealed an impressive estrogen receptor molecular polymorphism. Given the recent finding of a similar estrogen receptor polymorphism at the messenger RNA level by several laboratories, it is tempting to speculate about its possible biological significance. To gain insight into the potential clinical relevance of this polymorphism in terms of breast cancer hormone dependence, we compared the 265 cytosols for their [3H]tamoxifen aziridine- and [3H]estradiol-binding capacities using the above-mentioned method and the conventional dextran-coated charcoal assay. We failed to identify a specific [3H]tamoxifen aziridine electrophoretic pattern with respect to the tumor estrogen receptor content as measured by the dextran-coated charcoal assay. However, an excellent correlation overall was found between the intensities of both labeling methods. Some tumors were positive for only one of these two ligands. It will be clinically important to see whether the tumors positive for [3H]tamoxifen aziridine only correspond to the small subset of tumors (10%) which respond to tamoxifen treatment despite very low estrogen receptor levels, as measured by the dextran-coated charcoal technique. |
